Alumis Stock Nearly Doubles on Psoriasis Drug Trial, FDA Plans

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib

Alumis (NASDAQ:ALMS), which develops targeted therapies for immune-mediated diseases, closed Tuesday’s session at $16.23, up 95.31%. Trading volume reached 64.1 million shares, coming in about 3,077% above its three-month average of 2 million shares.Tuesday's move followed Phase 3 psoriasis data for envudeucitinib, which investors are treating as a potential commercial inflection point. The focus is now watching New Drug Application (NDA) timing…

Alumis shoots up as its Sotyktu rival aces psoriasis trials

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.

Alumis stock nearly doubles on psoriasis drug trial, FDA plans

Alumis soars as TYK2 drug hits mark in psoriasis trials

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral options for psoriasis, among them drugs from Takeda and Johnson & Johnson.

Should You Chase the Rally in Alumis Stock Today?

Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.

Alumis reports positive Phase III data for envudeucitinib in plaque psoriasis

Alumis has announced positive top line data from its Phase III ONWARD1 and ONWARD2 clinical trials evaluating envudeucitinib in adults with moderate-to-severe plaque psoriasis.The post Alumis reports positive Phase III data for envudeucitinib in plaque psoriasis appeared first on Clinical Trials Arena.